Market capitalization | $6.92m |
Enterprise Value | $3.63m |
P/E (TTM) P/E ratio | negative |
P/B ratio (TTM) P/B ratio | 1.08 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-7.27m |
Cash position | $3.29m |
EPS (TTM) EPS | $-5.08 |
P/E forward | negative |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
2 Analysts have issued a Adial Pharmaceuticals, Inc. forecast:
2 Analysts have issued a Adial Pharmaceuticals, Inc. forecast:
Dec '23 |
+/-
%
|
||
Net Profit | -7.75 -7.75 |
39%
39%
|
|
Depreciation and Amortization | - - |
-
|
|
Stock Compensation | 1.75 1.75 |
48%
48%
|
|
Operating Cash Flow | -6.81 -6.81 |
39%
39%
|
|
Investments | - - |
-
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | - - |
-
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.
Head office | United States |
CEO | Cary Claiborne |
Employees | 7 |
Founded | 2010 |
Website | www.adialpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.